Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 3714 |
| PDBID: | 7EOW |
| Chains: | B_A |
| Organism: | Homo sapiens |
| Method: | XRD |
| Resolution (Å): | 1.60 |
| Reference: | 10.1016/j.bbrc.2021.06.030 |
| Antibody | |
| Antibody: | caplacizumab Nanobody |
| Antibody mutation: | No |
| INN (Clinical Trial): | Caplacizumab(Approved) |
| Antigen | |
| Antigen: | von Willebrand factor |
| Antigen mutation: | No |
| Durg Target: | P04275 |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >7EOW_B|Chain B|caplacizumab|Homo sapiens (9606) MEVQLVESGGGLVQPGGSLRLSCAASGRTFSYNPMGWFRQAPGKGRELVAAISRTGGSTYYPDSVEGRFTISRDNAKRMVYLQMNSLRAEDTAVYYCAAAGVRAEDGRVRTLPSEYTFWGQGTQVTVSSLEHHHHHH |
Antigen
Chain: A
Mutation: NULL
| >7EOW_A|Chain A|von Willebrand factor|Homo sapiens (9606) MGSSHHHHHHSSGENLYFQSGSHMDISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVEYHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRITLLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVLSSVDELEQQRDEIVSYLCDLAPEAPPPT |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: ARG28 THR29 PHE30 SER31 TYR32 SER53 ARG54 THR55 SER58 ASN75 ALA76 ARG78 GLY101 ARG103 ALA104 GLU105 ASP106 GLY107 ARG108 A: SER27 GLU28 PRO29 PRO30 LEU31 HIS32 ASP33 PHE34 TYR35 CYS36 SER37 ARG38 LEU39 ARG72 LYS76 TRP77 CYS222 ASP223 GLU227 ALA228 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
